logo image
search icon
Global Allogenic Cell Therapies Market

Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell, Regulatory T-Cell), By Source of Cell, By Target Indication, By Therapeutic Area, Region And Segment Forecasts, 2023-2031.

Report ID : 1084 | Published : 2024-03-14 | Pages: 180 | Format:

The Allogeneic Cell Therapy Market Size is valued at 997.36 Million in 2022 and is predicted to reach 2853.34 Million by the year 2031 at a 12.7 % CAGR during the forecast period for 2023-2031.

Allogeneic Cell Therapy Market

Global Allogeneic cell therapies use the transfer of cells from a donor to a patient. Stem cells collected from the donor whose tissue type closely matches that of the patient are predominantly utilized in allogeneic cell therapies. There are various sources to get allogeneic cells, among which blood is taken from the placenta, and the umbilical cord of newborns is the prominent source of cells for allogeneic transplants. The small volume of blood comprises a high number of cells that are eligible to multiply quickly.

Moreover, raising prevalence of chronic diseases and increasing funding for stem cell research start-ups are driving the growth of allogeneic stem cell therapy market. Currently, many companies are developing a wide range of tissue-engineered products and allogeneic cell therapies aiming to bring about an era of regenerative medicine to treat people with unmet medical needs. Additionally, a rise in the prevalence of cancer and cardiovascular diseases is expected to boost the global allogeneic stem cell therapy market. For instance, JKastrup has an ongoing Phase II clinical trial for allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure.

 Market Segmentation

The Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Based on the cell type, the market is divided into Cardiosphere-derived cells (CDCS), fibroblasts, t-cells, mesenchymal stem cells (MSCS), hematopoietic stem cells (HSCS) and others. Based on cell/tissue source, the market is segmented into skin, blood, PBC, BM and others. Based on the indication, the market is divided into acute graft-versus-host disease (gvhd), chronic ulcers and diabetic foot ulcers, osteoarthritis, crohn’s disease, cardiovascular disease, solid tumors/cancers and others (alzheimer’s disease, etc). Based on region, the maarket is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.

Competitive Landscape

Some of The Key Players in The Allogeneic Cell Therapy Market:

  • TCR² Therapeutics
  • TiGenix (Takeda)
  • Adaptimmune Therapeutics plc,
  • Adicet Bio, Inc.,
  • Allogene Therapeutics,
  • Allogene Therapeutics,
  • Artiva Biotherapeutic,
  • Atara Biotherapeutics,
  • Athersys, Inc.,
  • BioCardia Inc.,
  • Bluebird Bio,
  • BlueRock Therapeutics LP,
  • Bone Therapeutics,
  • Capricor Therapeutics,
  • Cell2Cure,
  • Cellectis,
  • Cellenkos,
  • Cellular Biomedicine Group,
  • Celularity,
  • Celyad,
  • Century Therapeutics,
  • CHABiotech,
  • CRISPR Therapeutics,
  • Cynata Therapeutics,
  • Cyto Therapeutics Pty Limited,
  • Fate Therapeutics,
  • Fate Therapeutics,
  • Fundamenta Therapeutics,
  • GammaDelta Therapeutics Limited,
  • GC Cell,
  • Hope Biosciences,
  • Immunity Bio,
  • Lineage Cell Therapeutics, Inc.,
  • MEDIPOST,
  • Mesoblast Ltd,
  • Nanjing Bioheng Biotech,
  • NantKwest,
  • Nkarta, Inc.,
  • Orca Bio,
  • Organogenesis Inc.,
  • Osiris Therapeutics, Inc.,
  • Pluristem Therapeutics Inc,
  • Poseida Therapeutics
  • Regeneus,
  • Stemedica Cell Technologies, Inc.,
  • Stempeutics

 The Allogeneic Cell Therapy Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 997.36 Million

Revenue Forecast In 2031

USD 2853.34 Million

Growth Rate CAGR

CAGR of 12.7 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Cell Therapy, By Source of Cell, By Target Indication, By Therapeutic Area

 

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio,Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, AbbVie, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm,Janssen Biotech, JW Therapeutics, Medisix Therapeutics, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, and Posedia Therapeutics, and Others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2.Executive Summary

Chapter 3.Global Allogeneic Cell Therapy Market Snapshot

Chapter 4.Global Allogeneic Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry

Chapter 5.Market Segmentation 1: By Type of Cell Therapy Estimates & Trend Analysis
5.1. By Type of Cell Therapy & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Type of Cell Therapy:
5.2.1. Virus-Specific T-Cell
5.2.2. Stem Cell
5.2.3. Regulatory T-Cell

Chapter 6.Market Segmentation 2: By Source of Cell Estimates & Trend Analysis
6.1. By Source of Cell & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Source of Cell:
6.2.1. Peripheral Blood
6.2.2. Bone Marrow
6.2.3. Umbilical Cord Blood
6.2.4. Adipose Tissue
6.2.5. Placenta

Chapter 7.Market Segmentation 3: By Target Indication Estimates & Trend Analysis
7.1. By Target Indication & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Target Indication:
7.2.1. Bone Disorder
7.2.2. Critical Limb Ischemia
7.2.3. Crohn’s Disease
7.2.4. Diabetic Foot Ulcer
7.2.5. Graft versus Host Disease
7.2.6. Leukemia
7.2.7. Lymphoma
7.2.8. Myelodysplastic Syndrome
7.2.9. Cytomegalovirus Infection
7.2.10. Others

Chapter 8.Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
8.1. By Therapeutic Area & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Therapeutic Area:
8.2.1. Oncological Disorders
8.2.2. Neurological Disorders
8.2.3. Musculoskeletal Disorder
8.2.4. Autoimmune / Inflammatory Disorders
8.2.5. Post-Transplant Infections

Chapter 9.Allogeneic Cell Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Type of Cell Therapy, 2023-2031
9.1.2. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.1.3. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.1.4. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.1.5. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada

9.2. Europe
9.2.1. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.2.2. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.2.3. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.2.4. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.2.5. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe

9.3. Asia Pacific
9.3.1. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.3.2. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.3.3. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.3.4. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.3.5. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific


9.4. Latin America
9.4.1. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.4.2. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.4.3. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.4.4. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.4.5. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America

9.5. Middle East & Africa
9.5.1. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, (US$ Million)
9.5.2. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.5.3. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.5.4. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.5.5. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA

Chapter 10.Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles

10.2.1. TCR² Therapeutics
10.2.2. TiGenix (Takeda)
10.2.3. Adaptimmune Therapeutics plc,
10.2.4. Adicet Bio, Inc.,
10.2.5. Allogene Therapeutics,
10.2.6. Allogene Therapeutics,
10.2.7. Artiva Biotherapeutic,
10.2.8. Atara Biotherapeutics,
10.2.9. Athersys, Inc.,
10.2.10. BioCardia Inc.,
10.2.11. Bluebird Bio,
10.2.12. BlueRock Therapeutics LP,
10.2.13. Bone Therapeutics,
10.2.14. Capricor Therapeutics,
10.2.15. Cell2Cure,
10.2.16. Cellectis,
10.2.17. Cellenkos,
10.2.18. Cellular Biomedicine Group,
10.2.19. Celularity,
10.2.20. Celyad,
10.2.21. Century Therapeutics,
10.2.22. CHABiotech,
10.2.23. CRISPR Therapeutics,
10.2.24. Cynata Therapeutics,
10.2.25. Cyto Therapeutics Pty Limited,
10.2.26. Fate Therapeutics,
10.2.27. Fate Therapeutics,
10.2.28. Fundamenta Therapeutics,
10.2.29. GammaDelta Therapeutics Limited,
10.2.30. GC Cell,
10.2.31. Hope Biosciences,
10.2.32. Immunity Bio,
10.2.33. Lineage Cell Therapeutics, Inc.,
10.2.34. MEDIPOST,
10.2.35. Mesoblast Ltd,
10.2.36. Nanjing Bioheng Biotech,
10.2.37. NantKwest,
10.2.38. Nkarta, Inc.,
10.2.39. Orca Bio,
10.2.40. Organogenesis Inc.,
10.2.41. Osiris Therapeutics, Inc.,
10.2.42. Pluristem Therapeutics Inc,
10.2.43. Poseida Therapeutics
10.2.44. Regeneus,
10.2.45. Stemedica Cell Technologies, Inc.,
10.2.46. Stempeutics

Global Allogeneic Cell Therapies Market Segmentation:

Allogeneic Cell Therapy Market

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) by Type of Cell Therapy

  • Virus-Specific T-Cell
  • Stem Cell
  • Regulatory T-Cell

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Source of Cell

  • Peripheral Blood
  • Bone Marrow
  • Umbilical Cord Blood
  • Adipose Tissue
  • Placenta

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Target Indication

  • Bone Disorder
  • Critical Limb Ischemia
  • Crohn’s Disease
  • Diabetic Foot Ulcer
  • Graft versus Host Disease
  • Leukemia
  • Lymphoma
  • Myelodysplastic Syndrome
  • Cytomegalovirus Infection
  • Others

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Therapeutic Area

  • Oncological Disorders
  • Neurological Disorders
  • Musculoskeletal Disorder
  • Autoimmune / Inflammatory Disorders
  • Post-Transplant Infections

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region

Europe Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • U.S.
  • Canada

Asia Pacific Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Allogeneic Cell Therapy Market Size?

The Allogeneic Cell Therapy Market is expected to grow at a 12.7 % CAGR during the forecast period for 2023-2031.

Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Biotechnology

Select Licence Type
$3786
$10000
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach